CRISPR Therapeutics has entered into an investment agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics’ 30-day volume-weighted average price. The financing is expected to close on or about February 27, 2024, subject to customary closing conditions. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a leading healthcare specialist investor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics’ Gene Therapy Wins EU Approval
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
- Is CRSP a Buy, Before Earnings?
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics price target lowered to $120 from $160 at Truist
